Renal cell carcinoma (RCC) is amongst the most immune-infiltrated solid tumours, but only a small subset of patients achieves durable response to immune checkpoint blockade therapy. Efforts to characterize the immune microenvironment and molecular regulators responsible for treatment responses have explored numerous fa...
Jennifer Q. Pfeil, Shirley Hui, Daniel Stueckmann et al.· bioRxiv· 0 citations
The preclinical studies demonstrate that both genetic deletion and pharmacologic inhibition of MPO significantly delayed pancreatic tumor growth and prolong survival through NK cell and T cell dependent mechanisms and identify MPO as a clinically relevant therapeutic target that remodels the immunosuppressive tumor mic...
Angisha Basnet, Kaitlyn M. Landreth, Benjamin C. Duncan et al.· Cancer Research· 0 citations
Malignant cells do not exist in isolation. In pancreatic ductal adenocarcinoma (PDAC), malignant cells reside within distinct spatial niches shaped by stromal, immune, endothelial, and neural compartments, and this spatial context is linked to therapeutic resistance and clinical outcome. While genomic alterations dri...
Sibyl Drissler, Noor Shakfa, Elizabeth Sunnucks et al.· Cancer Research· 0 citations
The findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification.
Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al.· Cancer Research· 0 citations
Human pancreatic cancer has a relatively homogenous genome and established classical and basal transcriptional subtypes, but despite this, there exist many intermediate state tumours, and a complex, spatially heterogeneous tumour microenvironment. To identify inter-omic dependencies, we investigated its genotype to p...
Hartland W. Jackson· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.